EKF Diagnostics Holdings plc specialises in the development, production and distribution of near patient analysers, clinical chemistry and DNA enrichment kits.
Our range of blood analysers are simple to use and designed to quickly deliver accurate results to aid the diagnosis of anemia, diabetes and associated conditions.
EKF analyzers are used in more than 70 countries by healthcare professionals in blood banks, GP surgeries, diabetes clinics, pharmacies, hospitals, sports medicine and laboratories.
We are also a worldwide leader in the manufacture and distribution of organ injury biomarkers specialising in acute injury to kidneys (AKI), liver and pancreas. Our microtitre plate assay kits have particular application in assessing the safety and effectiveness of drug candidates in clinical trials.
EKF Diagnostics recently acquired the UK-based technology company, 360 Genomics, gaining access to their gene detection technologies; PointManTM and CounterPoint™. 360 Genomics then went on to become EKF Molecular Diagnostics Ltd a subsidiary of EKF Diagnostics Holdings Plc. The EKF Molecular management team has a wealth of experience in the global field of molecular diagnostics. This was shortly followed by the acquisition of Selah Genomics Inc and DiaSpect Medical AB in early 2014 further adding to the diversity of EKF Diagnostics product portfolio.
Today EKF Diagnostics has distributors in more than 100 locations around the globe, multi-national research and manufacturing facilities, teams of experienced analysts and engineers in Germany, Ireland, USA and the UK and a board led by some of foremost authorities in medical diagnostics in the world.
Company Growth (employees)